Teton Advisors Inc. Cuts Stake in BioTelemetry Inc (NASDAQ:BEAT)

Teton Advisors Inc. reduced its stake in shares of BioTelemetry Inc (NASDAQ:BEAT) by 1.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 131,000 shares of the medical research company’s stock after selling 2,000 shares during the period. Teton Advisors Inc.’s holdings in BioTelemetry were worth $6,308,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. State of Alaska Department of Revenue lifted its holdings in shares of BioTelemetry by 1.8% during the 1st quarter. State of Alaska Department of Revenue now owns 11,327 shares of the medical research company’s stock worth $709,000 after acquiring an additional 195 shares during the period. Pearl River Capital LLC lifted its holdings in shares of BioTelemetry by 104.0% during the 1st quarter. Pearl River Capital LLC now owns 408 shares of the medical research company’s stock worth $26,000 after acquiring an additional 208 shares during the period. Chatham Capital Group Inc. lifted its holdings in shares of BioTelemetry by 0.7% during the 1st quarter. Chatham Capital Group Inc. now owns 32,397 shares of the medical research company’s stock worth $2,029,000 after acquiring an additional 214 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of BioTelemetry by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 12,898 shares of the medical research company’s stock worth $808,000 after acquiring an additional 233 shares during the period. Finally, Mark Sheptoff Financial Planning LLC lifted its holdings in shares of BioTelemetry by 25.0% during the 1st quarter. Mark Sheptoff Financial Planning LLC now owns 1,500 shares of the medical research company’s stock worth $94,000 after acquiring an additional 300 shares during the period. Institutional investors and hedge funds own 90.84% of the company’s stock.

NASDAQ BEAT traded up $1.64 during mid-day trading on Friday, hitting $40.98. The company’s stock had a trading volume of 403,500 shares, compared to its average volume of 492,701. BioTelemetry Inc has a 52-week low of $38.78 and a 52-week high of $80.92. The stock’s fifty day simple moving average is $45.47 and its two-hundred day simple moving average is $56.08. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.19 and a quick ratio of 2.09. The firm has a market capitalization of $1.33 billion, a P/E ratio of 21.12, a price-to-earnings-growth ratio of 1.99 and a beta of 1.32.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, July 30th. The medical research company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.08. BioTelemetry had a net margin of 11.06% and a return on equity of 22.98%. The firm had revenue of $111.80 million for the quarter, compared to analyst estimates of $111.11 million. During the same quarter last year, the firm posted $0.46 earnings per share. BioTelemetry’s revenue for the quarter was up 10.3% compared to the same quarter last year. On average, equities analysts forecast that BioTelemetry Inc will post 1.98 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the stock. Raymond James lowered shares of BioTelemetry from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Lake Street Capital set a $90.00 price target on shares of BioTelemetry and gave the company a “buy” rating in a report on Wednesday, July 31st. BidaskClub lowered shares of BioTelemetry from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 23rd. Sidoti cut their price target on shares of BioTelemetry from $95.00 to $87.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Finally, ValuEngine lowered shares of BioTelemetry from a “hold” rating to a “sell” rating in a report on Thursday, July 18th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. BioTelemetry currently has an average rating of “Hold” and a consensus target price of $72.57.

BioTelemetry Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

See Also: What are popular green investing opportunities?

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.